[go: up one dir, main page]

FR08C0039I1 - - Google Patents

Info

Publication number
FR08C0039I1
FR08C0039I1 FR08C0039C FR08C0039I1 FR 08C0039 I1 FR08C0039 I1 FR 08C0039I1 FR 08C0039 C FR08C0039 C FR 08C0039C FR 08C0039 I1 FR08C0039 I1 FR 08C0039I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22094096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0039(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR08C0039I1 publication Critical patent/FR08C0039I1/fr
Application granted granted Critical
Publication of FR08C0039I2 publication Critical patent/FR08C0039I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR08C0039C 1997-12-31 2008-07-21 Composes azapolycycliques fusionnes avec un aryle Active FR08C0039I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7024597P 1997-12-31 1997-12-31
PCT/IB1998/001813 WO1999035131A1 (fr) 1997-12-31 1998-11-13 Composes azapolycycliques fusionnes avec un aryle

Publications (2)

Publication Number Publication Date
FR08C0039I1 true FR08C0039I1 (fr) 2008-11-14
FR08C0039I2 FR08C0039I2 (fr) 2009-12-18

Family

ID=22094096

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0039C Active FR08C0039I2 (fr) 1997-12-31 2008-07-21 Composes azapolycycliques fusionnes avec un aryle

Country Status (51)

Country Link
US (6) US6410550B1 (fr)
EP (2) EP1044189B2 (fr)
JP (1) JP3550359B2 (fr)
KR (1) KR100408138B1 (fr)
CN (2) CN1324013C (fr)
AP (1) AP1170A (fr)
AR (1) AR017967A1 (fr)
AT (1) ATE386024T1 (fr)
AU (1) AU753389C (fr)
BG (1) BG65058B1 (fr)
BR (2) BR9814592B1 (fr)
CA (1) CA2316921C (fr)
CO (1) CO4810373A1 (fr)
CY (2) CY1107391T1 (fr)
CZ (1) CZ301925B6 (fr)
DE (2) DE122008000038I1 (fr)
DK (1) DK1044189T4 (fr)
DZ (1) DZ2697A1 (fr)
EA (1) EA003190B1 (fr)
EG (1) EG23816A (fr)
ES (1) ES2301210T5 (fr)
FR (1) FR08C0039I2 (fr)
GT (2) GT199800200AA (fr)
HN (1) HN1998000177A (fr)
HR (2) HRP20050506A2 (fr)
HU (2) HU230297B1 (fr)
IL (2) IL136727A0 (fr)
IS (1) IS5514A (fr)
LU (1) LU91442I2 (fr)
MA (1) MA26589A1 (fr)
ME (1) ME00459B (fr)
MY (1) MY118163A (fr)
NL (1) NL300355I2 (fr)
NO (2) NO319115B1 (fr)
NZ (1) NZ504482A (fr)
OA (1) OA11428A (fr)
PA (1) PA8463901A1 (fr)
PE (1) PE20000053A1 (fr)
PL (1) PL209404B1 (fr)
PT (1) PT1044189E (fr)
RS (1) RS50069B (fr)
SA (1) SA99191123B1 (fr)
SG (1) SG102686A1 (fr)
SI (1) SI1044189T2 (fr)
SK (1) SK286886B6 (fr)
TN (1) TNSN98237A1 (fr)
TR (1) TR200001840T2 (fr)
TW (1) TW513412B (fr)
UA (1) UA66825C2 (fr)
WO (1) WO1999035131A1 (fr)
ZA (1) ZA9811911B (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
EP1044189B2 (fr) * 1997-12-31 2015-02-25 Pfizer Products Inc. Composes azapolycycliques fusionnes avec un aryle
PT1202736E (pt) 1999-07-28 2008-12-29 Univ Leland Stanford Junior Nicotina na angiogénese e vasculogénese terapêuticas
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
WO2002085843A2 (fr) * 2001-04-20 2002-10-31 Pfizer Products Inc. Procede de preparation d'indenes 1,3-substitues et composes azapolycycliques d'aryle fondus
HRP20030910B1 (hr) * 2001-05-14 2011-11-30 Pfizer Products Inc. Tartaratne soli 5,8,14-triazatetraciklo {10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>}-heksadeka-2(11), 3,5,7,9-pentaena i pripadajućih farmaceutskih spojeva
OA12600A (en) 2001-05-14 2006-06-09 Pfizer Prod Inc The citrate salt of 5,8,14-triazatetracyclo 10.3.1.o2,11.o49)-hexadeca-2(11)3,5,7,9-pentaene and pharmaceutical compositions thereof.
PL374325A1 (en) * 2001-11-29 2005-10-17 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
CN1596128A (zh) * 2001-11-30 2005-03-16 辉瑞产品公司 5,7,14－三氮杂四环[10.3.1.0(2,11).0(4,9)]－十六碳－2(11)3,5,7,9－五烯的药物组合物
WO2003045967A1 (fr) 2001-11-30 2003-06-05 Pfizer Products Inc. Composes azapolycycliques a fusion aryle
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
ES2361993T5 (es) * 2002-02-14 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento con enzimas de productos alimenticios para celiaquía
WO2003096979A2 (fr) * 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Pharmacotherapie destinee a une maladie coeliaque
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7776545B2 (en) * 2002-11-20 2010-08-17 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for Celiac Sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
MXPA05005366A (es) * 2002-11-20 2005-08-03 Pfizer Prod Inc Un metodo para preparar acido indano-1,3-dicarboxilico.
WO2004048318A1 (fr) * 2002-11-25 2004-06-10 Pfizer Products Inc. Procede ameliore pour la preparation d'indenes 1,3-substitutees
AU2004203983A1 (en) * 2003-01-15 2004-07-29 Pfizer Products Inc. Process for the preparation of aryl fused polycyclic lactams
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
EP1633358A1 (fr) * 2003-05-20 2006-03-15 Pfizer Products Inc. Compositions pharmaceutiques a base de varenicline
ATE405566T1 (de) * 2003-06-04 2008-09-15 Pfizer Prod Inc Herstellung von substituierten chinoxalinen aus den dianilinen mit 2,3-dihydroxy-1,4-dioxan
WO2005007630A2 (fr) * 2003-07-21 2005-01-27 Pfizer Products Inc. Composes azapolycycliques fusionnes avec aryle
EP1648893B1 (fr) * 2003-07-21 2009-09-23 Pfizer Products Inc. Composes azapolycycliques fusionnes avec heteroaryle pour reduire la dependance a la nicotine
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
WO2006006071A1 (fr) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution de compose azapolycyclique fusionne aryle
US7766018B2 (en) 2004-09-30 2010-08-03 Smoke-Break, Inc. Device and composition for reducing the incidence of tobacco smoking
AU2006217616A1 (en) * 2005-02-24 2006-08-31 Pfizer Products Inc. Preparation of high purity substituted quinoxaline
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
EP1976495A2 (fr) * 2006-01-06 2008-10-08 Aarhus Universitet Composes agissant sur le transporteur de la serotonine
WO2007110730A2 (fr) * 2006-03-27 2007-10-04 Pfizer Products Inc. Etalons de varenicline et temoins d'impuretes
BRPI0710914A2 (pt) * 2006-04-24 2011-09-27 Pfizer Prod Inc forma de dosagem e método para o tratamento de dependência, adição e supressão de nicotina, em particular para uso na terapia para parar de fumar
US20100234349A1 (en) 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
AU2007319951A1 (en) * 2006-11-09 2008-05-22 Pfizer Products Inc. Polymorphs of nicotinic intermediates
BRPI0808987A2 (pt) * 2007-03-16 2014-09-09 Univ Leland Stanford Junior Terapia combinatória de enzima para digestão de glúten dietético
WO2009034431A2 (fr) 2007-09-10 2009-03-19 Pfizer Inc. Formes posologiques à libération contrôlée de la varenicline
EP2260037A2 (fr) * 2008-02-15 2010-12-15 Medichem, S.A. Nouvelle forme polymorphe d'un dérivé de pyrazino[2,3-h][3]-benzazépine
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
EP2271344A4 (fr) 2008-03-31 2011-04-27 Univ South Florida Méthodes de traitement d'une ataxie et d'un déséquilibre non-ataxique induits par une maladie
US8039620B2 (en) 2008-05-22 2011-10-18 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline L-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (fr) * 2008-09-01 2011-06-22 Actavis Group PTC EHF Procédé de fabrication de varénicline, intermédiaires de la varénicline et leurs sels pharmaceutiquement acceptables
EP2204369A1 (fr) 2008-12-22 2010-07-07 Medichem, S.A. Procédé de préparation de la varénicline et intermédiaires y afférent
JP2012517471A (ja) * 2009-02-11 2012-08-02 スノビオン プハルマセウトイカルス インコーポレイテッド ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法
CA2801842A1 (fr) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Co-precipites amorphes de tartrate de varenicline
RU2012102052A (ru) 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
EP2475662A2 (fr) * 2009-09-11 2012-07-18 Sunovion Pharmaceuticals Inc. Agonistes de la histamine h3 en sens inverse et les antagonistes et les procédés pour leur utilisation.
CA2791460A1 (fr) 2010-03-09 2011-09-15 Actavis Group Ptc Ehf Varenicline de haute purete ou son sel pharmaceutiquement acceptable sensiblement exempt d'impurete methylvarenicline
KR101109389B1 (ko) * 2010-04-30 2012-01-30 삼성전기주식회사 인쇄회로기판 및 그 제조방법
WO2011140431A1 (fr) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Sels de la varénicline et leurs formes cristallines
US20120004239A1 (en) 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
CN103619354A (zh) 2011-06-30 2014-03-05 东丽株式会社 止痒剂
ITMI20111413A1 (it) 2011-07-28 2013-01-29 Dipharma Francis Srl Procedimento per la preparazione di vareniclina
ES2426838B1 (es) 2012-04-20 2014-05-07 Genetracer Biotech S.L Método para predecir el éxito en el abandono del consumo de tabaco en respuesta a un tratamiento farmacológico
ES2426517B1 (es) 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
CN103570502A (zh) * 2012-07-18 2014-02-12 上海科胜药物研发有限公司 一种伐伦克林中间体的制备方法
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN103992272B (zh) * 2014-06-09 2016-05-11 安徽省逸欣铭医药科技有限公司 一种盐酸喷他佐辛酯、其制备方法及其用途
KR20160126697A (ko) 2015-04-24 2016-11-02 한미정밀화학주식회사 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물
KR20160143407A (ko) 2015-06-05 2016-12-14 한미정밀화학주식회사 신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
CN106674194B (zh) * 2016-12-14 2019-03-05 山东省联合农药工业有限公司 一种结构新颖的烟碱类杀虫剂及其制备方法和用途
JP7137850B2 (ja) 2017-03-03 2022-09-15 シーティーシー バイオ インク バレニクリンまたはその薬学的に許容可能な塩の包接複合体を含む口腔投与用製剤
KR102463733B1 (ko) 2017-06-30 2022-11-04 한미약품 주식회사 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물
WO2018154395A2 (fr) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Composition pharmaceutique à libération contrôlée de varénicline
KR20200034293A (ko) 2018-09-21 2020-03-31 한미약품 주식회사 제어 방출용 바레니클린 제제
ES3039903T3 (en) 2020-04-28 2025-10-27 Oyster Point Pharma Inc Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
CN113956255A (zh) * 2020-07-20 2022-01-21 威智医药有限公司 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法
WO2022035434A1 (fr) 2020-08-14 2022-02-17 Almatica Pharma Llc Co-cristal de varénicline et d'acide oxalique, composition pharmaceutique correspondante et méthodes d'utilisation correspondantes
US11040983B1 (en) 2020-08-14 2021-06-22 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022147189A1 (fr) * 2020-12-30 2022-07-07 Antares Pharma, Inc. Promédicaments de varénicline
WO2022222019A1 (fr) * 2021-04-20 2022-10-27 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Synthèse totale de varénicline
CN113277993B (zh) * 2021-06-06 2023-07-21 湖南第一师范学院 一种Tafamidis及其衍生物的合成方法
WO2023275413A2 (fr) 2021-12-23 2023-01-05 Medichem, S.A. Formulations pharmaceutiques solides de varénicline
EP4241775A1 (fr) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Comprimé de varénicline et son procédé de fabrication
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
WO2023244584A1 (fr) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Composés inhibiteurs d'aldh-2 et procédés d'utilisation
WO2024095172A1 (fr) 2022-11-04 2024-05-10 Pfizer Inc. Promédicaments de varénicline et composés contenant des amines vulnérables
IT202300003888A1 (it) 2023-03-03 2024-09-03 Dipharma Francis Srl Processo di preparazione di un farmaco usato per trattare la dipendenza da nicotina
WO2024224270A1 (fr) 2023-04-24 2024-10-31 Pfizer Inc. Formulations de varénicline

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) * 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
WO1997011072A1 (fr) † 1995-09-22 1997-03-27 Novo Nordisk A/S Nouveaux composes azacycliques ou azabicycliques a substitution
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
EP1044189B2 (fr) * 1997-12-31 2015-02-25 Pfizer Products Inc. Composes azapolycycliques fusionnes avec un aryle
AU1918299A (en) * 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
EP0955301A3 (fr) * 1998-04-27 2001-04-18 Pfizer Products Inc. Dérivés de 7-aza-bicyclo[2.2.1]-heptane, leur préparation et utilisation sur la base d'affinité pour les recepteurs de l'acetylcholine nicotinique neuronaux
HUP0103340A3 (en) * 1998-04-29 2002-10-28 Pfizer Prod Inc Aryl fused azapolycyclic compounds and pharmaceutical compositions thereof
WO2000044755A1 (fr) * 1999-01-29 2000-08-03 Abbott Laboratories Derives diazabicycliques utiles en tant que ligands du recepteur nicotinique de l'acetylcholine
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
OA12600A (en) * 2001-05-14 2006-06-09 Pfizer Prod Inc The citrate salt of 5,8,14-triazatetracyclo 10.3.1.o2,11.o49)-hexadeca-2(11)3,5,7,9-pentaene and pharmaceutical compositions thereof.
HRP20030910B1 (hr) * 2001-05-14 2011-11-30 Pfizer Products Inc. Tartaratne soli 5,8,14-triazatetraciklo {10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>}-heksadeka-2(11), 3,5,7,9-pentaena i pripadajućih farmaceutskih spojeva
PL374325A1 (en) * 2001-11-29 2005-10-17 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
WO2003045967A1 (fr) * 2001-11-30 2003-06-05 Pfizer Products Inc. Composes azapolycycliques a fusion aryle
CN1596128A (zh) * 2001-11-30 2005-03-16 辉瑞产品公司 5,7,14－三氮杂四环[10.3.1.0(2,11).0(4,9)]－十六碳－2(11)3,5,7,9－五烯的药物组合物
WO2005007630A2 (fr) * 2003-07-21 2005-01-27 Pfizer Products Inc. Composes azapolycycliques fusionnes avec aryle

Also Published As

Publication number Publication date
RS50069B (sr) 2009-01-22
CY1107391T1 (el) 2010-07-28
GT199800200AA (es) 2000-06-07
LU91442I2 (fr) 2008-07-21
US6951938B2 (en) 2005-10-04
MY118163A (en) 2004-09-30
NO319115B1 (no) 2005-06-20
DE69839131D1 (de) 2008-03-27
DE69839131T3 (de) 2015-05-07
BR9814592B1 (pt) 2010-06-01
HUS1600018I1 (hu) 2018-05-02
US6887884B2 (en) 2005-05-03
SK9712000A3 (en) 2002-03-05
AP9801422A0 (en) 1998-12-31
HN1998000177A (es) 1999-02-09
YU40300A (sh) 2003-10-31
CN1285821A (zh) 2001-02-28
EP1044189B2 (fr) 2015-02-25
ATE386024T1 (de) 2008-03-15
KR20010033823A (ko) 2001-04-25
DK1044189T4 (en) 2015-03-30
ZA9811911B (en) 2000-06-29
CY2008013I1 (el) 2009-11-04
IL136727A (en) 2006-06-11
CN1715280A (zh) 2006-01-04
NO20003422D0 (no) 2000-06-30
SK286886B6 (sk) 2009-07-06
AU753389C (en) 2007-08-09
DE69839131T2 (de) 2009-02-05
EG23816A (en) 2007-09-19
TNSN98237A1 (fr) 2005-03-15
SI1044189T2 (sl) 2015-05-29
EP1659114A2 (fr) 2006-05-24
BG65058B1 (bg) 2007-01-31
AP1170A (en) 2003-06-30
EA200000592A1 (ru) 2000-12-25
EP1044189B1 (fr) 2008-02-13
BR9816186B1 (pt) 2009-01-13
PL341824A1 (en) 2001-05-07
AU753389B2 (en) 2002-10-17
NO2006016I1 (no) 2006-11-27
EP1659114A3 (fr) 2007-01-17
TW513412B (en) 2002-12-11
US20070275973A1 (en) 2007-11-29
PL209404B1 (pl) 2011-08-31
HUP0100949A3 (en) 2002-12-28
NO2006016I2 (fr) 2008-10-20
US20020072524A1 (en) 2002-06-13
SG102686A1 (en) 2004-03-26
SI1044189T1 (sl) 2008-06-30
US6897310B2 (en) 2005-05-24
CO4810373A1 (es) 1999-06-30
HU230297B1 (hu) 2015-12-28
IS5514A (is) 2000-05-26
CY2008013I2 (el) 2009-11-04
ME00459B (me) 2011-10-10
CN1324013C (zh) 2007-07-04
AR017967A1 (es) 2001-10-24
KR100408138B1 (ko) 2003-12-01
DE122008000038I1 (de) 2008-11-13
EP1044189A1 (fr) 2000-10-18
AU9641698A (en) 1999-07-26
PT1044189E (pt) 2008-04-22
BR9814592A (pt) 2000-10-17
DZ2697A1 (fr) 2003-03-29
PA8463901A1 (es) 2000-09-29
LU91442I9 (fr) 2018-12-31
MA26589A1 (fr) 2004-12-20
DK1044189T3 (da) 2008-05-13
BG104561A (en) 2001-01-31
US20020132824A1 (en) 2002-09-19
US6410550B1 (en) 2002-06-25
NO20003422L (no) 2000-08-29
TR200001840T2 (tr) 2000-12-21
GT199800200A (es) 2000-06-07
HRP20000445B1 (hr) 2009-04-30
HRP20000445A2 (en) 2001-04-30
CA2316921A1 (fr) 1999-07-15
NL300355I2 (nl) 2008-11-03
NL300355I1 (nl) 2008-08-01
NZ504482A (en) 2003-01-31
JP3550359B2 (ja) 2004-08-04
HUP0100949A2 (hu) 2001-08-28
US20020111350A1 (en) 2002-08-15
IL136727A0 (en) 2001-06-14
CZ20002438A3 (cs) 2002-11-13
HRP20050506A2 (en) 2006-03-31
FR08C0039I2 (fr) 2009-12-18
PE20000053A1 (es) 2000-02-07
WO1999035131A1 (fr) 1999-07-15
JP2002500218A (ja) 2002-01-08
SA99191123B1 (ar) 2006-10-02
HK1031878A1 (en) 2001-06-29
US20020072525A1 (en) 2002-06-13
CA2316921C (fr) 2004-12-07
OA11428A (en) 2004-05-03
EA003190B1 (ru) 2003-02-27
CZ301925B6 (cs) 2010-08-04
UA66825C2 (uk) 2004-06-15
ES2301210T3 (es) 2008-06-16
ES2301210T5 (es) 2015-05-07

Similar Documents

Publication Publication Date Title
BE2018C032I2 (fr)
FR08C0039I1 (fr)
CH0944937H2 (fr)
ITMI970390V0 (fr)
ITMI971197A0 (fr)
ITTO970411A0 (fr)
ITMI971092A0 (fr)
BE2013C047I2 (fr)
BR9701757A (fr)
IN185465B (fr)
IN185765B (fr)
ITVR970024V0 (fr)
ITRM970387A0 (fr)
ITMI971427A0 (fr)
ITRM970147V0 (fr)
IN191791B (fr)
BR9700653A (fr)
IN186649B (fr)
CN3054556S (fr)
CN3055113S (fr)
CN3053500S (fr)
CN3053525S (fr)
CN3059024S (fr)
CN3053852S (fr)
CN3054099S (fr)